Page last updated: 2024-10-21

2-amino-5-phosphonovalerate and Epilepsy, Absence

2-amino-5-phosphonovalerate has been researched along with Epilepsy, Absence in 8 studies

2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.

Epilepsy, Absence: A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's4 (50.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Strauss, U1
Kole, MH1
Bräuer, AU1
Pahnke, J1
Bajorat, R1
Rolfs, A1
Nitsch, R1
Deisz, RA2
Badiu, CI1
Avanzini, G1
de Curtis, M1
Franceschetti, S1
Sancini, G1
Spreafico, R1
Chrobok, L1
Palus, K1
Jeczmien-Lazur, JS1
Chrzanowska, A1
Kepczynski, M1
Lewandowski, MH1
Stewart, LS1
Wu, Y1
Eubanks, JH1
Han, H1
Leschenko, Y1
Perez Velazquez, JL1
Cortez, MA1
Snead, OC1
Lacey, CJ1
Bryant, A1
Brill, J1
Huguenard, JR1
Sasaki, S1
Huda, K1
Inoue, T1
Miyata, M1
Imoto, K1

Other Studies

8 other studies available for 2-amino-5-phosphonovalerate and Epilepsy, Absence

ArticleYear
An impaired neocortical Ih is associated with enhanced excitability and absence epilepsy.
    The European journal of neuroscience, 2004, Volume: 19, Issue:11

    Topics: 2-Amino-5-phosphonovalerate; Animals; Blotting, Western; Brain; Disease Models, Animal; Dose-Respons

2004
Sensitivity of thalamic GABAergic currents to clonazepam does not differ between control and genetic absence epilepsy rats.
    Brain research, 2004, Nov-12, Volume: 1026, Issue:2

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Antic

2004
Cortical versus thalamic mechanisms underlying spike and wave discharges in GAERS.
    Epilepsy research, 1996, Volume: 26, Issue:1

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cerebral Cortex; Disease

1996
The GABA(B) receptor antagonist CGP 55845A reduces presynaptic GABA(B) actions in neocortical neurons of the rat in vitro.
    Neuroscience, 1999, Volume: 93, Issue:4

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Delta

1999
Disinhibition of the intergeniculate leaflet network in the WAG/Rij rat model of absence epilepsy.
    Experimental neurology, 2017, Volume: 289

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Age Factors; Animals; Animals, Newborn; Disease Models, Animal

2017
Severity of atypical absence phenotype in GABAB transgenic mice is subunit specific.
    Epilepsy & behavior : E&B, 2009, Volume: 14, Issue:4

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Animals, Newborn; Autoradiography; Cognition Disorder

2009
Enhanced NMDA receptor-dependent thalamic excitation and network oscillations in stargazer mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Aug-08, Volume: 32, Issue:32

    Topics: Action Potentials; Animals; Biophysical Phenomena; Calcium Channels; Disease Models, Animal; Electri

2012
Impaired feedforward inhibition of the thalamocortical projection in epileptic Ca2+ channel mutant mice, tottering.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Mar-15, Volume: 26, Issue:11

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Age Factors; Animals; Calcium Channel Block

2006